Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children aged 1 to 5 years previously vaccinated with three or four doses of IPV (Group 1) or unvaccinated infants aged 6 weeks (-7 to +14 days) (Groups 2 and 3).~2. For Groups 2 and 3 (enrolled at 6 weeks of age) infants must have been vaccinated with 3 doses of bOPV and one dose of IPV prior to administration of the study vaccine, and the last Polio vaccine must have been administered at least 4 weeks prior to the study vaccine.~3. Healthy without obvious medical conditions that preclude the subject to be in the study as established by the medical history and physical examination.~4. Written informed consent obtained from 1 or 2 parent(s) or legal guardian(s) as per country regulations.~Exclusion Criteria:~1. For Group 1: polio vaccines within the 3 months prior to the administration of the study vaccine (number of previous polio vaccine doses to be documented). For Groups 2 and 3: polio vaccines prior to administration of the study vaccine other than 3 doses of bOPV and 1 dose of IPV .~2. Any confirmed or suspected immunosuppressive or known immunodeficient condition including human immunodeficiency virus (HIV) infection.~3. Family history of congenital or hereditary immunodeficiency.~4. Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).~5. Known allergy to any component of the study vaccines or to any antibiotics.~6. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections (of IPV).~7. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~8. Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination (the child can be included at a later time if within age window and all in/exclusion criteria are met.).~9. Member of the subject's household (living in the same house or apartment unit) has received OPV in the last 3 months.~10. Subject who, in the opinion of the Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- SABIN monovalent OPV2 vaccine (Type: EXPERIMENTAL): SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid

Based on this trial design, predict the completion outcome and termination type (if applicable).